2641 completed, 581 terminated, 558 unknown, 516 recruiting. 4971 Phase 2, 899 Phase 1, 461 Phase 3.
Follow Brain Diseases: new trials by email Literature Review of Brain Diseases trials Research Report on Brain Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Terazosin And Metabolic Energetics in Parkinson's Disease Terazosin 5 MG, Placebo - Parkinson's Disease (PD) | Phase 2 | Suspended | Ergun Y. Uc | 120 | 2028-07-01 | 2026-10-09 |
| Phase 1/2 Study Evaluating the Safety, PK/PD, and Clinical Activity of Oral JBI-778 in Patients With Brain Metastases, Leptomeningeal Disease, or Recurrent High Grade Glioma JBI-778 - Brain Metastases From Solid Tumors, Leptomeningeal Disease | Phase 1 / Phase 2 | Not yet recruiting | Jubilant Therapeutics Inc. | 113 | 2028-04-01 | 2026-08-07 |
| Sodium Lactate in Severe TBI Sodium Lactate, placebo - Traumatic Brain Injury | Phase 2 | Not yet recruiting | University of California, Los Angeles | 264 | 2028-01-10 | 2026-01-16 |
| Study to Evaluate the Safety, Tolerability, Efficacy, and PK of FHL-301 in Parkinson's Disease Patients. Gemfibrozil, Placebo - Parkinson Disease | Phase 2 | Withdrawn | Forest Hills Lab | 2027-11-01 | 2026-08-19 | |
| Terazosin for Dementia With Lewy Bodies Terazosin Hydrochloride, Placebo - Dementia With Lewy Bodies | Phase 1 / Phase 2 | Not yet recruiting | Qiang Zhang | 40 | 2027-10-01 | 2026-03-12 |
| AV-1959R Vaccine in Individuals With Preclinical Alzheimer's Disease AV-1959R, Placebo - Preclinical Alzheimer's Disease, Alzheimer Disease | Phase 2 | Not yet recruiting | Institute for Molecular Medicine | 160 | 2027-10-01 | 2026-10-21 |
| A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects With Early Parkinson's Disease MT101-5 - Parkinson's Disease | Phase 2 | Not yet recruiting | Mthera Pharma Co., Ltd. | 120 | 2027-09-01 | 2026-10-16 |
| Terazosin And Metabolic Engagement in Alzheimer's Disease Terazosin (Hytrin), Placebo - Alzheimer s Disease | Phase 2 | Not yet recruiting | Qiang Zhang | 100 | 2027-08-01 | 2026-09-01 |
| A Multicenter Study to Assess the Feasibility of 5-Aminolevulinic Acid (5-ALA) in Pediatric Brain Tumor Patients Aminolevulinic acid hydrochloride - Pediatric Brain Tumor | Phase 2 | Not yet recruiting | Costas Hadjipanayis | 20 | 2027-08-01 | 2026-10-07 |
| H3K27M-specific Immune Effector Cells Targeting DMG/DIPG H3K27M-EIEs - Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-10-30 |
| Memantine Targeting Neurovascular Dysfunction After Mild and Moderate Traumatic Brain Injury (MEND) Memantine - Traumatic Brain Injury, Mild Traumatic Brain Injury | Phase 2 | Not yet recruiting | Nova Scotia Health Authority | 45 | 2027-06-01 | 2026-10-09 |
| Remotely Administered tDCS to Improve Cognitive Function in Veterans With mTBI and PTSD Principal Investigator Transcranial direct current stimulation (tDCS), Cognitive training - Cognition, Brain Injuries | Phase 2 | Not yet recruiting | VA Office of Research and Development | 46 | 2027-05-24 | 2026-02-17 |
| Valproic AcId for Traumatic BRAin INjury Trial Valproic Acid (VPA), Standard of care treatment + normal saline - Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury | Phase 2 / Phase 3 | Not yet recruiting | Northwestern University | 432 | 2027-05-01 | 2026-11-05 |
| Intranasal Stem Cells to Treat Perinatal Brain Injury to Combat Cerebral Palsy MSC, marrow, Placebo - Perinatal Arterial Ischemic Stroke, Perinatal Asphyxia | Phase 2 / Phase 3 | Not yet recruiting | UMC Utrecht | 162 | 2027-04-01 | 2026-09-21 |
| Sustained Release Oral Formulation For Treatment Of Parkinsons Disease Formulation A, Formulation B, Formulation C - Healthy Volunteers | Phase 1 / Phase 2 | Not yet recruiting | University of Minnesota | 32 | 2027-04-01 | 2026-10-01 |
| Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG Opdualag - High Grade Glioma, Diffuse Intrinsic Pontine Glioma | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 12 | 2027-03-01 | 2026-09-09 |
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG) Tovorafenib - High Grade Glioma (HGG) of the Brain With BRAF Aberration, High Grade Glioma (III or IV) | Phase 2 | Not yet recruiting | Nationwide Children's Hospital | 79 | 2027-02-01 | 2026-10-20 |
| IDH1-vac in Patients With Newly Diagnosed IDH1R132H-positive High-grade Astrocytomas IDH1-vac, IS-vac, Temozolomide (TMZ) - Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4 | Phase 2 | Not yet recruiting | German Cancer Research Center | 216 | 2027-02-01 | 2026-10-22 |
| A Study of AB-1005 Gene Therapy in Japanese Adults With Moderate Parkinson's Disease (J-REGENERATE-PD) AB-1005 - Parkinson Disease | Phase 2 | Not yet recruiting | Bayer | 8 | 2027-01-25 | 2026-07-29 |
Showing 20 of 4971. Sign in to see all of them.
Brain Neoplasms (783) · Alzheimer Disease (713) · Parkinson Disease (602) · Stroke (541) · Ischemic Stroke (370) · Glioblastoma (295) · Dementia (227) · Epilepsy (203) · Cognitive Dysfunction (194) · Glioma (194) · Brain Injuries, Traumatic (169) · Migraine Disorders (169) · Gliosarcoma (155) · Central Nervous System Neoplasms (147) · Astrocytoma (142)
Nervous System Diseases (4905) · Central Nervous System Diseases (4890) · Neurodegenerative Diseases (1591) · Pathological Conditions, Signs and Symptoms (1216) · Cardiovascular Diseases (1206) · Vascular Diseases (1199) · Cerebrovascular Disorders (1119) · Mental Disorders (1104) · Neurocognitive Disorders (970) · Neoplasms by Site (886) · Neoplasms (880) · Nervous System Neoplasms (861) · Basal Ganglia Diseases (825) · Movement Disorders (792)
Temozolomide (118) · Bevacizumab (83) · Sodium Chloride (80) · Saline Solution (64) · Radiotherapy (59) · Donepezil (45) · Radiosurgery (42) · Carboplatin (41) · Transcranial Direct Current Stimulation (40) · Aspirin (35) · Cyclophosphamide (31) · Levodopa (31) · pembrolizumab (31) · Levetiracetam (28) · Tissue Plasminogen Activator (28)
National Cancer Institute (NCI) (67) · National Institute of Neurological Disorders and Stroke (NINDS) (57) · Pfizer (53) · Duke University (48) · Novartis Pharmaceuticals (45) · M.D. Anderson Cancer Center (38) · Chang Gung Memorial Hospital (35) · Johns Hopkins University (34) · Assistance Publique - Hôpitaux de Paris (32) · Eli Lilly and Company (29) · Beijing Tiantan Hospital (28) · GlaxoSmithKline (27) · Massachusetts General Hospital (27) · Merck Sharp & Dohme LLC (26) · VA Office of Research and Development (25)
United States (2670) · Canada (435) · France (432) · United Kingdom (406) · Germany (403) · China (366) · Spain (325) · Italy (274) · Australia (264) · Netherlands (197) · Poland (158) · Belgium (147) · Japan (133) · South Korea (132) · Israel (124)
PMID 37870112, PMID 33175411, PMID 36463457, PMID 36602886, PMID 38588457, PMID 33974419, PMID 35305920, PMID 38489195, PMID 40680102, PMID 19775921, PMID 25918556, PMID 27657681, PMID 28403842, PMID 31356217, PMID 34532852, PMID 39800465, PMID 40603145, PMID 20185783, PMID 21586746, PMID 22163120, PMID 24144944, PMID 25671797, PMID 25726502, PMID 29480210, PMID 32250312, PMID 32593547, PMID 33189083, PMID 33236783, PMID 33482890, PMID 34349180, PMID 34906976, PMID 36289001, PMID 37059702, PMID 37624739, PMID 38114596, PMID 38706271, PMID 40368603, PMID 41114449, PMID 11112243, PMID 16135345, PMID 16574919, PMID 17175134, PMID 17941858, PMID 18296121, PMID 18662331, PMID 19233036, PMID 19453963, PMID 19834014, PMID 20548058, PMID 20651267
2023 (50), 2014 (37), 2015 (35), 2018 (31), 2017 (29), 2019 (28), 2009 (26), 2016 (25), 2008 (22), 2025 (22), 2005 (9), U01CA062399 (9), 2004 (8), U01CA137443 (6), U10CA025224 (6)